SENESCO TECHNOLOGIES, INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • October 9th, 2015 • Sevion Therapeutics, Inc. • Services-commercial physical & biological research • New Jersey
This Indemnification Agreement ("Agreement") is made as of [ ], 2014 by and between Senesco Technologies, Inc., a Delaware corporation (the "Company"), and [ ] ("Indemnitee").
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 9th, 2015 • Sevion Therapeutics, Inc. • Services-commercial physical & biological research
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of 2015, among the undersigned corporation (the “Company”), and each signatory hereto (each, an “Investor” and collectively, the “Investors”). Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the Subscription Agreement (as defined below).
SUBSCRIPTION AGREEMENTSubscription Agreement • October 9th, 2015 • Sevion Therapeutics, Inc. • Services-commercial physical & biological research • New York
This Subscription Agreement (this “Agreement”) is being delivered to the purchaser identified on the signature page to this Agreement (the “Subscriber”) in connection with its investment in the securities of Sevion Therapeutics, Inc., a Delaware corporation (the “Company”). The Company is conducting a private placement (the “Offering”) of a minimum of One Million Five Hundred Thousand Dollars ($1,500,000) (the “Minimum Offering Amount”) and a maximum of up to Ten Million Dollars ($10,000,000) (the “Maximum Offering Amount”) of units (the “Units”) at a purchase price of $0.75 per Unit (the “Purchase Price”) with each Unit consisting of (i) one share (the “Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”) (or, at the election of any Subscriber who, as a result of the ownership of the Common Stock would hold in excess of 4.99% of the Company’s issued and outstanding Common Stock, shares of Series C Convertible Preferred Stock (the “Preferred Shares”),
Nondisclosure, Noncompetition and Invention Assignment AgreementNoncompetition and Invention Assignment Agreement • October 9th, 2015 • Sevion Therapeutics, Inc. • Services-commercial physical & biological research • New Jersey
This Nondisclosure, Noncompetition and Invention Assignment Agreement (this “Agreement”) is made by and between Senesco Technologies, Inc., a Delaware corporation, and its wholly-owned subsidiaries, Senesco, Inc., a New Jersey corporation and Fabrus, Inc., a Delaware corporation (hereinafter collectively, the “Employer”) and [___] (“Employee”), to be effective as of [ ], 2014:
SEVION THERAPEUTICS, INC. AMENDMENT NO. 1 TO SUBSCRIPTION AGREEMENTSubscription Agreement • October 9th, 2015 • Sevion Therapeutics, Inc. • Services-commercial physical & biological research • New York
This Amendment (this "Amendment") effective as of [ ], 2015 (the "Effective Time"), between Sevion Therapeutics, Inc., a Delaware corporation (the "Company"), and the investor signatory hereto (the "Purchaser"), sets forth certain modifications and amendments to the Subscription Agreement (as defined below). Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Subscription Agreement. Except as specifically agreed to, waived or consented to herein, the terms of the Transaction Documents shall remain in full force and effect.
FORM OF COMMON STOCK PURCHASE WARRANT SEVION THERAPEUTICS, INC.Sevion Therapeutics, Inc. • October 9th, 2015 • Services-commercial physical & biological research
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Issuance Date (the “Initial Exercise Date”) and on or prior to the close of business on the thirty (30) month anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from SEVION THERAPEUTICS, INC., a Delaware corporation (the “Company”), up to [ ] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
